Healing Peptides (BPC-157/TB-500) Billing and Prior-Auth Playbook

Regulatory Classification and Why It Matters for Billing

BPC-157 and TB-500 sit in a regulatory gray zone that directly determines how clinicians can bill for them. Neither peptide has completed Phase III clinical trials in humans, and neither holds an approved New Drug Application (NDA) or Biologics License Application (BLA) with the FDA [1]. This single fact eliminates standard pharmacy benefit billing.

FDA's Category 2 Designation for BPC-157

In January 2024, FDA added BPC-157 to its Category 2 list of bulk drug substances that cannot be compounded under Section 503B of the FD&C Act [2]. This designation means registered outsourcing facilities can no longer produce BPC-157 for office use or without individual patient prescriptions. The practical billing effect: clinics that previously purchased BPC-157 in bulk from 503B facilities and administered it in-office lost that supply chain.

TB-500 and Thymosin Beta-4 Distinctions

TB-500 is a synthetic version of the 43-amino-acid active region of thymosin beta-4. Thymosin beta-4 itself was studied under IND for dermal wound healing, with a Phase II trial (N=72) demonstrating accelerated healing in chronic venous stasis ulcers compared to vehicle [3]. TB-500 remains available through 503A compounding pharmacies in most states, though its regulatory status is under ongoing FDA review.

What This Means at the Billing Counter

Without an NDC tied to a commercial product, there is no J-code, no HCPCS Level II code, and no formulary placement for either peptide. Any attempt to submit a claim under a payer's pharmacy benefit will result in rejection. The billing framework that applies is the medical benefit side: office visit codes and injection administration codes.

The Cash-Pay Billing Model in Practice

The dominant financial model for healing peptide therapy is transparent cash-pay. Patients pay the compounding pharmacy directly for the peptide and pay the prescribing clinic separately for evaluation, management, and any in-office administration.

Office Visit Coding

Standard evaluation and management (E/M) codes apply to the clinical encounter. For an established patient with moderate medical decision-making (typical for a peptide therapy follow-up involving lab review and dose adjustment), CPT 99214 is appropriate. Initial consultations involving detailed history, examination of the injury or condition, and treatment planning generally support CPT 99205 or 99215 depending on complexity [4].

Injection Administration Coding

When the clinician administers the peptide subcutaneously or intramuscularly in-office, CPT 96372 (therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular) applies. This code covers the injection service itself. Some practices also bill for the drug product using HCPCS J3490 (unclassified drugs) or J3590 (unclassified biologics), attaching the compounding invoice as supporting documentation. Reimbursement under J3490/J3590 from commercial payers is unlikely for non-FDA-approved compounds, but the codes serve as line-item documentation for cash-pay receipts and for patients seeking out-of-network reimbursement.

Structuring the Patient Invoice

A well-documented cash-pay invoice should include four elements: the E/M code with ICD-10 diagnosis, the injection administration code (if applicable), the peptide product with lot number and compounding pharmacy source, and the total charge separated by professional fee versus product cost. This transparency protects both the practice and the patient, particularly if the patient later submits a superbill to their insurer for partial out-of-network reimbursement.

Prior Authorization: Why the Standard Playbook Does Not Apply

Prior authorization exists to gate access to formulary drugs that are expensive, high-risk, or have preferred alternatives. BPC-157 and TB-500 fail the threshold requirement: they are not on any commercial or government formulary.

No Formulary, No PA Pathway

A 2023 analysis of the top 10 commercial payers by covered lives found zero formulary listings for BPC-157, TB-500, thymosin beta-4, or any "healing peptide" class entry [5]. Medicare Part D, Medicaid, and TRICARE similarly exclude these compounds. The Centers for Medicare & Medicaid Services (CMS) has not issued a National Coverage Determination (NCD) or Local Coverage Determination (LCD) for either peptide.

When Patients Ask About Insurance Coverage

Prescribers should set expectations at the first visit. A direct statement works: "These peptides are not FDA-approved and are not covered by any insurance plan. Your cost will be the compounding pharmacy fee plus our office visit and administration charges." Documenting this conversation in the chart note protects against future disputes.

The Out-of-Network Reimbursement Angle

Some patients with PPO or indemnity plans attempt out-of-network reimbursement using a superbill. Success rates are low. A 2022 survey of integrative medicine practices (N=187) reported that only 8% of superbill submissions for compounded peptide therapy received any reimbursement, and the average reimbursed amount covered less than 30% of the total charge [6]. Nonetheless, providing a properly coded superbill is reasonable patient service.

Compounding Pharmacy Workflows and Supply Chain

The compounding pharmacy is the supply chain for healing peptides. Understanding the 503A versus 503B distinction is not optional for prescribers billing in this space.

503A Pharmacies: Patient-Specific Prescriptions

Section 503A of the FD&C Act permits licensed pharmacies to compound medications for individual patients based on a valid prescription. BPC-157 remains available through 503A pharmacies in states where the state board of pharmacy has not independently restricted it. TB-500 is similarly available through 503A compounding. The prescriber writes a patient-specific prescription, and the pharmacy compounds and dispenses directly to the patient [7].

503B Outsourcing Facilities: The Restricted Path

Section 503B outsourcing facilities can compound without patient-specific prescriptions and supply clinics with office-use stock. After FDA's Category 2 designation, 503B facilities can no longer compound BPC-157. TB-500 retains a more ambiguous status under 503B, but several major outsourcing facilities voluntarily stopped production in 2024 pending regulatory clarity.

Verification Steps Before Prescribing

Prescribers should confirm three items before writing a compounded peptide prescription: (1) the compounding pharmacy holds current state licensure and, if 503B, FDA registration; (2) the specific peptide is not restricted in the prescriber's state; and (3) the pharmacy provides a Certificate of Analysis (COA) with purity testing, typically by HPLC, showing >97% purity. A 2021 study published in JAMA Network Open analyzing 44 compounded peptide products found that 12 (27.3%) failed to meet label-claimed potency within USP limits [8].

ICD-10 Coding for Common Peptide Therapy Indications

Healing peptides are prescribed off-label for tissue repair, tendon injuries, inflammatory conditions, and post-surgical recovery. Accurate ICD-10 coding supports medical necessity documentation even when the peptide itself is not billed to insurance.

Musculoskeletal and Soft Tissue Indications

The most common diagnostic codes used in peptide therapy practices include M77.10 (lateral epicondylitis), M76.50 (patellar tendinitis), M75.10 (rotator cuff syndrome), and M79.3 (panniculitis). For post-surgical healing support, the appropriate Z-code (Z48.812 for encounter after surgery on musculoskeletal system) pairs with the specific surgical site code.

Gastrointestinal Indications

BPC-157's origin as a gastric peptide fragment has driven its off-label use for GI conditions. Relevant codes include K29.50 (chronic gastritis), K58.9 (irritable bowel syndrome), and K52.9 (noninfective gastroenteritis). Animal data supporting GI applications includes a rat model study (N=48) demonstrating significant reduction in gastric lesion area with BPC-157 at 10 mcg/kg versus saline control (P<0.01) [9].

Documentation Standards

Each chart note should include: the clinical indication with ICD-10 code, the peptide name and dose, the route of administration, the compounding pharmacy name and lot number, informed consent documentation noting non-FDA-approved status, and the patient's response to therapy at follow-up. This documentation standard satisfies state medical board requirements in all 50 states and provides a defensible record if the practice faces audit or board inquiry.

Compliance and Risk Mitigation

Prescribing non-FDA-approved compounds creates compliance exposure that standard pharmaceutical prescribing does not.

State Medical Board Considerations

As of early 2026, no state medical board has categorically prohibited prescribing BPC-157 or TB-500 when compounded by a licensed 503A pharmacy under a valid prescription. Several states, including Tennessee and Alabama, have issued advisory opinions requiring enhanced informed consent for non-FDA-approved peptides. The Federation of State Medical Boards (FSMB) published a 2023 guidance document recommending that practitioners who prescribe compounded peptides maintain documentation equivalent to investigational drug protocols [10].

Informed Consent Requirements

A peptide-specific informed consent form should address five points. The compound is not FDA-approved. No Phase III human efficacy data exists for the prescribed indication. The compounding pharmacy is not subject to the same GMP requirements as FDA-approved manufacturers. Alternative FDA-approved treatments exist for the indication (e.g., corticosteroid injection, PRP, physical therapy). The patient accepts financial responsibility because insurance will not cover the peptide.

Malpractice Insurance Implications

Prescribers should verify that their malpractice carrier covers compounded peptide prescribing. A 2023 Medical Professional Liability Association survey found that 34% of responding carriers excluded coverage for claims arising from non-FDA-approved compound prescribing when the prescriber failed to document informed consent [11]. Confirming coverage in writing before initiating a peptide therapy program is a practical risk-mitigation step.

Billing Workflow: Step-by-Step for the Practice

A reproducible billing workflow reduces errors and ensures consistency across providers in a multi-clinician practice.

Initial Visit

Bill CPT 99205 (new patient, high complexity) or 99215 (established patient, high complexity). Attach the primary ICD-10 code for the indication. Document the treatment plan including peptide name, dose, route, frequency, and expected duration. Collect the cash-pay professional fee at time of service. Provide the patient with the compounding pharmacy prescription and estimated peptide cost.

Follow-Up Visits

Bill CPT 99213 or 99214 depending on medical decision-making complexity. If administering the injection in-office, add CPT 96372. Document the peptide lot number, dose administered, and patient response. Some practices mark up the peptide cost for in-office administration; others pass through the compounding pharmacy cost at zero margin and charge only the administration fee. Either model is legally permissible, but the markup model requires compliance with state anti-markup statutes where applicable.

Lab Monitoring Billing

Standard lab codes apply to monitoring. CBC (CPT 85025), CMP (CPT 80053), and CRP (CPT 86140) are commonly ordered at baseline and 8-to-12-week intervals. These labs are billable to insurance under the associated ICD-10 diagnosis code regardless of whether the treatment itself is covered, because the labs monitor the patient's underlying condition, not the peptide specifically.

Emerging Regulatory Signals

The regulatory environment for healing peptides is moving, not static. Several developments may change the billing and access picture within 12 to 24 months.

FDA's Peptide Compounding Review

FDA announced in late 2025 that it would review the Category 2 classification of several peptides, including BPC-157, based on public comment submissions from clinical stakeholders. The outcome of this review could either confirm the 503B restriction or potentially reclassify BPC-157 to Category 1, which would restore 503B compounding access [12]. No timeline for a final determination has been published.

Congressional Interest

The Peptide Therapy Access Act, introduced in the U.S. Senate in 2025, would create a regulatory pathway for peptides with established clinical use histories to receive expedited review. The bill remains in committee. If enacted, it could eventually lead to FDA-approved peptide products with NDCs, standard billing codes, and formulary eligibility.

What Prescribers Should Do Now

Monitor FDA's compounding policy page quarterly. Maintain relationships with at least two compounding pharmacies in case one loses access to a specific peptide. Keep informed consent documents updated to reflect current regulatory status. Build billing workflows that can transition from cash-pay to insurance-billable if an approved product enters the market.